Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Celularity Equity Warrants Exp 16 July 2026 CELUW

Financial Services Healthcare Biotechnology
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CELUW)

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

GlobeNewswire 7 days ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

GlobeNewswire April 22, 2024

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

GlobeNewswire April 19, 2024

Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024

GlobeNewswire April 18, 2024

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

GlobeNewswire April 15, 2024

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

GlobeNewswire April 8, 2024

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

GlobeNewswire March 26, 2024

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

GlobeNewswire March 20, 2024

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

GlobeNewswire March 14, 2024
View More News ››

Opinion & Analysis (NDAQ:CELUW)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CELUW)

Be the first to post on this bullboard.

Sandstorm Gold Ltd.

Sandstorm Gold Ltd.

Sandstorm Gold Ltd. is a Canada-based precious metals-focused streaming and royalty company. The Company is focused on ...
View More »